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Aim: The purpose of this study was to assess the prescription of epoetins and consumption 
of health care resources (in terms of drug treatments) in naïve patients with hematological 
malignancies in a real-world setting; in particular, we compared the results between reference 
product and biosimilar products.
Methods: An observational retrospective study based on administrative and laboratory databases 
of three local health units was conducted. All adults diagnosed with hematological malignancies 
and who had received at least one epoetin (either reference product or biosimilars) prescription 
for the first time between 1 January 2010 and 30 April 2012 (enrollment period) were included. 
The date of the first prescription of epoetin within the enrollment period was defined as index 
date (ID). Patients were followed up for 4 weeks after ID (follow-up period) and were inves-
tigated for the 1-year period before the ID. The difference between the last hemoglobin (Hb) 
measurement after ID and the one prior to ID (ΔHb) was evaluated. The drug cost analysis was 
conducted from the perspective of the Italian National Health System.
Results: Overall, 69 patients were included in the study; 48 of them received reference epoetin 
product and 21 received biosimilars as first prescription. Among reference product users, the 
mean ± standard deviation (SD) age was 62.5±14.7 years; this cohort of patients was slightly 
significantly younger than the biosimilar users (71.8±11.8 years). The mean ± SD overall Hb 
level prior to treatment was lower among patients who started with biosimilar products (9.6±1.1 
g/dL) compared to those who started with a reference product (10.1±2.1 g/dL). No significant 
differences in ΔHb were observed between biosimilar and originator groups during the follow-
up period. The mean ± SD cost per patient was €667.98±573.93 and €340.85±235.73 for the 
reference product and biosimilar users, respectively (p=0.065).
Conclusion: Our study showed that the use of biosimilar products might contribute to control-
ling health care costs (in terms of drug treatments) for patients with hematological malignancies 
being maintained by high-quality anemia therapy. Our findings also showed some discordances 
regarding the most appropriate therapeutic approach in daily clinical practice.
Keywords: erythropoiesis-stimulating agents, chemotherapy-induced anemia, biosimilar, 
real-world setting
Introduction
Anemia is a condition in which the red blood cell mass is insufficient to adequately deliver 
oxygen to peripheral tissues. Patients with anemia related to cancer, chronic inflammation, 
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or chronic kidney disease (cKD) generally display a reduced 
response of endogenous erythropoietin (ePO) to trigger levels 
of hemoglobin (Hb); this aspect is worsened in those who are 
concomitantly receiving myelotoxic chemotherapy.1,2 Anemia 
may significantly impair quality of life, increase cardiovascular 
risk, and reduce long-term survival, when left untreated.3
earlier, treatment options were essentially limited to 
blood transfusions. The introduction of recombinant human 
ePO and an erythropoietic stimulating agent (eSA) in 1989 
resulted in a major progress in the treatment of anemia and 
provided a key tool for managing this condition in patients 
with cKD or cancer.4–7
In December 2004, the patent of epoetin-alpha (i.e. 
eprex®, reference product or originator [Janssen-cilag, 
Neuss, germany]) expired and this opened the way to 
biosimilars. currently, in europe three biosimilar products 
have received marketing authorization from the european 
Medicines Agency (eMA): Binocrit® [Sandoz gmbH, 
 Holzkirchen, germany] (epoetin-alpha; also known as 
Abseamed® [Medice Arzneimittel Putter gmbH & co., 
Iserlohn, germany] and epoetin Alfa Hexal® [Hexal  Biotech 
Forschungs gmbH, Holzkirchen, germany]), retacrit® 
[Hospira,  Maidenhead, United Kingdom] (epoetin-zeta; also 
called Silapo® [Stada r&D Ag, Bad Vilbel,  germany]), 
and eporatio® [ratiopharm gmbH, Ulm, germany] 
( epoetin- theta; also known as Biopoin® [Teva gmbH, Ulm, 
germany]).8 Since 2007, biosimilars of eSAs are available 
on the Italian market.9,10 According to the eMA guidelines, 
a biosimilar is defined as a biological medicinal product 
that is developed to be similar to an existing biological (the 
“reference medicine”). A biosimilar demonstrates similar-
ity to the reference medicinal product in terms of quality 
characteristics, biological activity, safety and efficacy based 
on a comprehensive comparability exercise.11
Although a biosimilar is approved based on its therapeutic 
equivalence, the interchangeability is still an open question 
mark;12 nevertheless, in accordance with the recent european 
directives and the last position paper from the Italian Medicines 
Agency (AIFA—Agenzia Italiana del Farmaco), biosimilar 
epoetins may be prescribed to naïve patients;13,14 however, the 
choice to treat a patient with a biological reference product or 
biosimilars is a clinical decision entrusted to the physician.13
Few real-life data and comparative analysis are available 
concerning the use of originator epoetins and biosimilar 
products in the Italian setting.15–19 The objective of the present 
study was to assess the prescription of epoetin and consump-
tion of health care resources (in terms of drug treatments) 
among naïve patients with hematological malignancies in an 
unselected Italian population under clinical practice setting; 
in particular, we compared the results between reference 
product and biosimilar products.
Methods
Data sources
The study was conducted using administrative databases 
of three Italian local health units (LHUs), geographically 
distributed throughout the national territory, representing 
~550,000 health-assisted individuals.
In particular, the following databases were used to retrieve 
the information: Beneficiaries, Hospital Direct Drugs Distri-
bution registry, Territorial Pharmacy, Hospital Discharges, 
Ambulatory care Specialist, Laboratory Analysis (which 
records the date and result of the Hb measurements), and the 
Mortalities, where only death dates are reported.
The diagnosis and procedures were retrieved using codes 
classified according to the International classification of Dis-
eases, Ninth revision, clinical Modification (IcD-9-cM). 
The information on drug prescriptions was identified through 
the International Anatomical Therapeutic chemical classifi-
cation system (ATc code).
To guarantee patient privacy, each subject was assigned an 
anonymous univocal numeric code. No identifiers related to 
patients were provided to the researchers. The patient code in 
each database permitted electronic linkage between all data-
bases. Informed consent is not required by the LHU ethics 
committees for using encrypted retrospective information. 
In compliance with the AIFA Determination20 guidelines 
for classification and conduction of observational studies on 
drugs and AIFA circular Procedures for launch of observa-
tional studies on drugs, this study was notified to the local 
ethics committee in each participating LHU according to the 
Italian law regarding the conduct of observational analysis 
and the LHU ethics committees approved the study.
Cohort definition
This study was an observational retrospective cohort analysis. 
All naïve patients aged ≥18 years who received at least one 
dispensing of epoetin (biosimilars [epoetin-alpha biosimilars: 
Binocrit and Abseamed; epoetin-zeta biosimilar: retacrit] 
or their corresponding reference medical product: eprex 
[ATc code: B03XA01]) during the enrollment period (from 
1 January 2010 to 30 April 2012) were considered eligible 
candidates for analysis and were enrolled. All these eSAs 
have been approved for the treatment of anemia induced by 
anticancer chemotherapy. The enrollment date was the first 
date on which a patient filled a prescription for one of these 
drugs during the enrollment period and was defined as the 
index date (ID); patients were followed up for 4 weeks since 
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then (follow-up period) and were investigated for the 1-year 
period before the ID (characterization period). Patients 
without epoetin prescriptions during the 6-month period 
preceding the ID were defined naïve.
Only those patients diagnosed with hematological malig-
nancies and who had at least one epoetin (either reference 
product or biosimilars) prescription for the first time during 
the enrollment period were included in the analysis.
All patients were stratified by the type of dispensed epo-
etin (either biosimilars or originator) at ID. Patients who 
were moved to other LHUs during the follow-up period were 
excluded from the analysis.
All enrolled patients were classified as follows: cancer 
patients based on the presence of at least one prescription of 
antineoplastic drugs (ATc code: L01) or endocrine therapy 
(ATc code: L02) or immunostimulant agents (ATc code: 
L03) or immunosuppressant agents (ATc code: L04); and/or at 
least one previous hospitalization with a primary or secondary 
diagnosis of neoplasms (IcD-9-cM codes: 140–239); and/or at 
least one hospitalization with a primary or secondary diagnosis 
of radiotherapy encounter (IcD-9-cM code: V580) or encoun-
ter for antineoplastic chemotherapy (IcD-9-cM code: V581).
cancer patients were classified as with or without hema-
tological malignancies based on previous hospitalization 
with primary or secondary diagnosis of malignant neoplasms 
of lymphatic and hematopoietic tissue (IcD-9-cM codes: 
200–208). Only patients with hematological malignancies 
were recruited in the analysis.
Data on baseline characteristics, including demographics, 
hospital admissions, prescribed drugs, and comorbidity, were 
collected. Specifically, the treatments of interest were anti-
hypertensive drugs (ATc codes: c02, c03, c07, c08, c09), 
oral hypoglycemic drugs and/or insulins (ATc code: A10), 
phosphate chelating agents (ATc code: V03Ae02), lanthanum 
carbonate (ATc code: V03Ae03), mineral supplements (cal-
cium, ATc code: A12AA), other mineral supplements (mag-
nesium, ATc code: A12cc), iron preparations (ATc code: 
B03A), sodium carbonate (ATc code: B05cB04), cardiac 
therapy (ATc code: c01), and vitamin D and analogs (ATc 
code: A11cc). Hospitalization related to diabetes was identi-
fied by IcD-9-cM code 250 (primary or accessory discharge 
reasons). Previous cardiovascular hospitalizations were iden-
tified by IcD-9-cM codes (primary or accessory discharge 
reasons); in particular, we identified myocardial infarction 
(IcD-9-cM codes: 410, 412); other forms of chronic isch-
emic heart disease (IcD-9-cM codes: 411, 413, 414), other 
cerebrovascular injuries (IcD-9-cM codes: 430–438), heart 
failure (IcD-9-cM code: 428); atherosclerosis, aneurysm, 
and dissection (IcD-9-cM codes: 440–442); other peripheral 
vascular diseases (IcD-9-cM codes: 440–443); and hyper-
tensive diseases (IcD-9-cM codes: 401–405).
Blood transfusion requirements (defined as a transfusion 
occurring during the follow-up period and for 2 months after 
the end of therapy) among patients initiated with originator or 
biosimilar epoetins were evaluated. In order to assess adequate 
control with therapeutic target, the Hb values (levels measured) 
were evaluated both in the last  measurement before the ID 
(from 2 months before the ID, value at baseline) and in the last 
available measurement around the end of the follow-up (up to 
2 months after ID, value at follow-up). The difference between 
the last Hb measurement after ID (value at follow-up) and the 
one prior to ID (value at baseline), defined as ΔHb, was also 
evaluated. Likewise, the mean dose of epoetin (once weekly) 
according to the Hb value at baseline was also evaluated. 
comorbidities were measured using the charlson comorbidity 
Index (ccI),21 and the sum of weights related to each condition 
(i.e. myocardial infarction, cancers, diabetes, ulcer) was identi-
fied through treatments and hospitalizations. All comorbidities 
during the characterization period were evaluated; the ccI 
score reflects a patient’s overall health status.
During the follow-up period, all epoetin prescriptions, 
in order to calculate the exposure to treatment, and all Hb 
measurements, in order to evaluate the achievement of the 
therapeutic targets, were evaluated.
costs analysis
The cost of therapy was evaluated during the follow-up period. 
costs are reported in euros (€). Drug costs were evaluated using 
the Italian National Health Service (NHS) purchase price. The 
cost analysis was conducted from the perspective of the NHS.
Statistical analysis
continuous variables are presented as mean ± standard devia-
tion (mean ± SD); categorical variables are shown as percent-
ages and absolute numbers. comparisons among groups were 
performed using analysis of variance and Pearson’s chi-square 
test for continuous and categorical data, respectively. Addition-
ally, the Kruskal–Wallis test was performed for asymmetric 
continuous variables (skewed). The post hoc Bonferroni 
correction was applied to account for multiple testing. The 
p-values ≤0.05 were considered to be statistically significant, 
and all statistical analyses were conducted using STATA soft-
ware, version 12.1 (Statacorp LP, college Station, TX, USA).
Results
A total of 1,143 patients were identified in the database as 
newly prescribed for eSA therapy from 1 January 2010 to 
30 April 2012. Overall, 37% of epoetin users were treated 
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for anemia induced by anticancer chemotherapy and were 
eligible for analysis. Overall, 69 (16.5% of all cancer patients) 
patients with hematological malignancies were included in 
the study. Of these, 48 and 21 patients (70% and 30% of 
all patients with hematological malignancies) received a 
 prescription for reference epoetin product and for biosimilars, 
respectively. Figure 1 shows details of the study’s inclusion 
and exclusion criteria. Figure 2 shows the percentage of 
patients stratified by hematologic cancer type at baseline. 
Patients’ diagnoses have been codified as follows: lymphoid 
leukemia (IcD-9-cM code: 204), 15%; myeloid leukemia 
(IcD-9-cM code: 205), 7%; Hodgkin’s disease (IcD-9-cM 
code: 201), 6%; multiple myeloma and immunoproliferative 
neoplasms (IcD-9-cM code: 203), 30%; non-Hodgkin’s 
lymphoma (grouped together under the diagnosis of other 
malignant neoplasms of lymphoid and histiocytic tissue and 
lymphosarcoma and reticulosarcoma and other specified 
malignant tumors of lymphatic tissue, IcD-9-cM codes: 200 
and 202), 42%. Of all patients enrolled, ~10% were treated 
for off-label indications (acute lymphoblastic leukemia 
[IcD-9-cM code: 204.0], acute myeloid leukemia [IcD-
9-cM code: 205.0], chronic myeloid leukemia [IcD-9-cM 
code: 205.1]).
Demographic and baseline clinical characteristics of the 
study population are shown in Table 1. gender was almost 
equally distributed among users of original reference and 
biosimilar products (on average, males: 50 and 52.4%, 
respectively). Among patients treated with reference product, 
Health-assisted individuals
 N=550,000  
Patients newly prescribed
 for ESA therapy from 
1 January 2010 to 30 April 2012 
N=1,143
Cancer patients
N=418 (37%)
Patients with hematologic
malignancies
N=69 (16.5%)
Originator
N=48 (70%)
Patients without
hematological malignancies
N=349 (83.5%)
Biosimilars
N=21 (30%)
Figure 1 Flowchart of cohort definition.
Abbreviation: esa, erythropoietic stimulating agent.
Multiple myeloma
and
immunoproliferative
neoplasms
30%Non-Hodgkin’s
lymphoma*
42%
Hodgkin’s disease
6% Myeloid leukemia
7%
Lymphoid leukemia
15%
Figure 2 Percentage of patients newly prescribed for erythropoiesis-stimulating agents, stratified by hematologic cancer type at baseline.
Note: *non-hodgkin’s lymphoma (grouped together under the diagnosis of other malignant neoplasms of lymphoid and histiocytic tissue and lymphosarcoma and 
reticulosarcoma and other specified malignant tumors of lymphatic tissue).
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Table 1 clinical and demographic characteristics by treatment group
Baseline characteristic Originator, n (%) Biosimilars, n (%) p-value
Patients 48 21
age, years 62.5±14.7 71.8±11.8 0.013
Male 24 (50.0) 11 (52.4) 0.856
Pre-index utilization
antihypertensive 23 (47.9) 9 (42.9) 0.698
Phosphate chelating agents – –
iron preparations n.i. n.i.
cardiac therapies n.i. 5 (23.8) 0.036
Vitamin D and analogs n.i. n.i.
Disease
Diabetes 11 (22.9) 4 (19.0) 0.720
charlson comorbidity index 0.477
charlson comorbidity index ≤1 6 (12.5) 4 (19.0)
charlson comorbidity index >1 42 (87.5) 17 (81.0)
cardiovascular disease 8 (16.7) 4 (19.0) 0.810
hemoglobin, g/dl* 10.1±2.1 9.6±1.1 0.410
Mean dose, iU/week** 32,344±28,756 30,976±20,362
Notes: *The Hb values were evaluated in the last measurement before the inclusion date of each patient (from 2 months before the inclusion date, value at baseline); **during 
the follow-up period. “–” indicates the relative results are 0. Data shown as number, mean ± SD, and n (%).
Abbreviations: SD, standard deviation; N.I., not issuable for data privacy; Hb, hemoglobin.
37.7% of all patients
60
,0
00
40
,0
00
20
,0
00
0
27.5% of all patients38,154±21,120
27.5% of all patients
7.3% of all patients
28,289±31,339
8,600±10,407
<10.0 10.0–12.0
Hemoglobin value (mg/dL)*
Mean Upper/lower
>12.0 n.a.
33,184±27,800
Figure 3 Mean dose (± standard deviation) of epoetin (once weekly) according to Hb value at baseline.
Note: *The Hb values were evaluated in the last measurement before the inclusion date of each patient (from 2 months before inclusion date, value at baseline).
Abbreviations: Hb, hemoglobin; n.a., not available.
the mean age (±SD) was found to be 62.5±14.7 years. Patients 
in this cohort were significantly younger than the biosimilar 
users (71.8±11.8 years), and the difference was statistically 
significant. The mean doses of epoetin were 32,344 IU/week 
(±28,756) and 30,976 IU/week (±20,362) for the reference 
product and biosimilar product groups, respectively (Table 1).
Figure 3 shows the mean dose (±SD) of epoetin (once 
weekly) according to Hb levels at baseline. Table 2 presents 
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the Hb values among the patients using either biosimilars 
or their reference product. Forty-four patients (about 64% 
of all enrolled patients) had data available regarding both 
the Hb values (at baseline and at follow-up). The mean 
Hb level before treatment was lower among patients who 
started with biosimilar products (9.5±1.1 g/dL) than those 
who started with a reference product of epoetin (10.0±2.2 
g/dL). During the follow-up period, the mean Hb level was 
10.8±1.8 g/dL in the biosimilar epoetin group and 11.3±1.9 
g/dL in the reference product group. There were no sig-
nificant differences between the two groups in ΔHb level. 
Up to 2 months after the end of therapy, blood transfusion 
was required by 9.5% of patients who received biosimilar 
epoetins and 10.4% of patients who received reference 
product, and the difference was not statistically significant 
(p=0.910; Figure 4).
The distribution of cost, according to the ongoing thera-
peutic strategy, is reported in Figure 5. The mean cost per 
1,
50
0
1,
00
0
50
0
0
€667.98±573.93
Originator
Mean Upper/lower
Biosimilars
€340.85±235.73
Figure 5 Mean (± standard deviation) cumulative cost of erythropoietic stimulating agents among patients initiated with originator and biosimilar products.
Note: p=0.065 (Kruskal–Wallis test).
Table 2 hemoglobin outcomes before and after the index date according to different epoetin treatments
Patients (N) Patients with baseline  
and follow-up Hb*, n (%)
Baseline  
Hb value*, mean ± SD
Follow-up  
Hb value*, mean ± SD
Δ%
Originator 48 28 (58.3) 10.0±2.2 11.3±1.9 +13.0
Biosimilars 21 16 (76.2) 9.5±1.1 10.8±1.8 +13.7
Note: *The Hb values were evaluated both in the last measurement before the index date (from 2 months before the index date, value at baseline) and in the last available 
measurement around the end of the follow-up period (up to 2 months after index date, value at follow-up).
Abbreviations: Hb, hemoglobin; SD, standard deviation.
10.4%
Originator
Pa
tie
nt
s 
th
at
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ce
iv
ed
 b
lo
od
tra
ns
fu
sio
n 
(%
)
Biosimilars
p=0.910
9.5%10.0
12.0
8.0
6.0
4.0
2.0
0.0
Figure 4 Blood transfusion requirements among patients according to the different 
epoetin treatments (originator or biosimilar products) up to 2 months after the 
end of therapy.
patient, attributable to the consumption of  epoetins used in 
the study period, was €667.98±573.93 and €340.85±235.73 
for the originator and biosimilar users, respectively. However, 
the difference was not statistically significant (p=0.065).
 
Bi
ol
og
ics
: T
ar
ge
ts
 a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
7.
20
4.
99
.2
50
 o
n 
16
-M
ar
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Biologics: Targets and Therapy 2016:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
163
Pharmacoutilization of epoetins in naïve patients
Discussion
In the present observational retrospective study, we evalu-
ated the epoetin utilization profiles and the consumption of 
health care resources (in terms of drug treatments) in naïve 
patients with hematological malignancies, in an unselected 
Italian population under clinical practice setting. In addition, 
we compared the results between reference product and 
biosimilar products.
During the past decade, epoetins have demonstrated a sig-
nificant therapeutic role for the management of cancer-related 
anemia in patients undergoing chemotherapy with an increase 
of Hb levels and improved quality of life.5,7,22 An important 
limitation of eSAs and biological medicines remains the high 
cost, which may limit access in some countries.23,24
Since the expiration of patent protection, a number 
of novel biosimilar epoetins have been approved on the 
world market.23,25 Biosimilar medicines have significant 
potential to offer cost savings to health care providers, but 
the global value of a biosimilar is not determined entirely 
by its pricing.26 During the last years, the health authorities 
have published specific guidelines establishing regulatory 
requirements for the approval and use of biosimilars, which 
are based on efficacy and safety comparability between 
biosimilar and reference product.11,14,23 Indeed, in order to 
be commercialized, a biosimilar must be proven equivalent 
to the reference product in terms of quality, safety, and 
effectiveness.23 This comparability exercise, which is the 
basis of the marketing authorization, should be considered 
sufficiently reassuring. regarding the use of biosimilar 
epoetins in Italy, the national authority responsible for drug 
regulation in Italy recommends prescribing biosimilars to 
treat naïve patients (e.g. patients never previously treated 
with epoetins or with previous exposure in time periods that 
are sufficiently distant).13
In this real-world assessment, almost 30% of all naïve 
patients with hematological malignancies being treated with 
epoetins received a prescription of biosimilar products. The 
national report on medicine use in Italy in 2014 showed 
that 55.9% of patients newly treated with epoetin-alpha (i.e. 
epoetin-alpha users without any prescription within the previ-
ous 6 months) were treated with biosimilars of epoetin-alpha, 
with an increasing trend as compared with the previous years 
(+54.6%).27 These data were retrieved by the Nationwide 
OsMed Health-DB Database and have been validated by 
AIFA to describe drug consumption nationwide.28
International evidence-based guidelines for the use of 
eSAs in cancer patients are currently being updated.5,29,30 As 
in other surveys,31,32 ~10% of all enrolled patients received 
an eSA for off-label indications. Available evidence does not 
identify Hb levels greater than or equal to 10 g/dL either as 
thresholds for starting eSA treatment or as targets for eSA 
therapy.30 These guidelines recommend that the clinicians 
should consider using eSAs for patients undergoing myelo-
toxic chemotherapy who have Hb threshold ≤10 g/dL to avoid 
the need for transfusions. Despite these recommendations, 
our findings showed that the mean Hb concentration was 
≥10 g/dL among originator users; likewise, patients who were 
initiated with reference product reported a higher Hb levels 
than those initiated with biosimilar products. It is interesting 
to note that there were no significant differences between 
the originator and biosimilar groups with regard to clinical 
characteristics at baseline, except that the patients undergo-
ing therapy with biosimilar products were older than those 
who started with reference product. Moreover, as observed 
in other studies,25,33,34 this study showed no significant differ-
ences between the two groups in ΔHb levels 2 months after 
the initiation of treatment.
Few studies have compared the impact of different 
eSA dosings or Hb targets on clinical and nonclinical out-
comes;35,36 the new recommendations5,30 suggested using 
the lowest possible eSA dose required to reduce the need 
for transfusions as well as reducing the eSA dose when Hb 
level exceeds 100 and 110 g/dL. Our data showed that in the 
cohort of patients we studied, the mean administered eSA 
dose was higher among the originator users than among the 
biosimilar users.
Transfusion reduction is the primary goal of epoetin 
therapy in treating cancer patients with chemotherapy-induced 
anemia.37 In this real-world study, the number of patients who 
required a transfusion was low (about 10% of all included 
patients) and generally similar across the different epoetin 
treatments. These data are consistent with the results of 
previous observational studies.34,38 The resource use and 
costs associated with eSA treatments have been reported 
previously.19,22,34,39,40 It is well known that one large potential 
advantage of biosimilars over existing reference biological 
products is cost savings, which could improve the access for 
some patients to medication. Although different methodologi-
cal approaches have been used to evaluate the cost of care, 
this study of real-world treatment patterns is in line with 
prior retrospective analyses.15,38 Our cost analysis suggested 
a lower mean drug cost in the group that received biosimilar 
epoetins compared with the group that received reference 
product, but there was no statistically significant difference 
between the groups; these findings require confirmation using 
more patients and more robust measures of cost-effectiveness.
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considering that biological medicines are among the most 
expensive pharmaceuticals available, the advent to market 
penetration of the currently available biosimilars could be an 
opportunity to relieve some of the financial pressure and a 
real strategy to improve the sustainability of NHS, especially 
in therapeutic areas where the demand and cost of new thera-
pies are high.41 The authors acknowledge some limitations 
of the study. In general, administrative database analyses 
limit the interpretation of results depending on the informa-
tion available. The major limitations are: small sample size, 
observational nature of the study design, and lack of clinical 
information from an administrative database. Therefore, no 
conclusions can be drawn concerning the possible underly-
ing confounders such as population bias, disease severity, or 
other individual circumstances. The limitation relates to the 
use of administrative data to select and describe our patient 
cohort, which did not permit to explore the diagnosis of each 
hematological malignancy more precisely. For example, reli-
ance on IcD-9-cM diagnostic codes to identify our cohort 
may have resulted in beneficiaries being included or excluded 
incorrectly. The limitation concerning limited data availability 
also did not permit to explore each reason for anemia more 
precisely.
Conclusion
Our data are in agreement with the relevant scientific lit-
erature and highlight how public and private payers, policy 
makers, and clinicians should be aware of the clinical equiva-
lence of biosimilars, in order to improve their appropriate 
prescription. Besides, biosimilar products may contribute to 
controlling health care costs for patients with hematological 
malignancies and being maintained by high-quality anemia 
therapy. At the same time, our findings showed that in the 
group of patients receiving a prescription of reference prod-
uct, the Hb concentration before treatment was ≥10 g/dL; 
evidence so far does not identify Hb levels ≥10 g/dL either 
as thresholds for initiating treatment or as targets for eSA 
therapy. As a consequence, it can be reasonably assumed 
that educational interventions as well as treatment strategies 
should be developed to improve the clinical management of 
these patients. given the nature of the study (observational 
and based on administrative databases), further analyses on a 
larger sample will contribute to refine and give more context 
to these results.
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